{
    "Case ID": "096997",
    "Crime_Name": [
        "Patent Infringement"
    ],
    "Crime_Type": [
        "Property Crimes"
    ],
    "Dispute_Type": [
        "Patent infringement dispute between brand-name and generic drug manufacturers"
    ],
    "Legal_Issue": [
        "Whether Apotex's Notice of Allegation (NOA) is justified based on non-infringement of the '668 and '762 patents"
    ],
    "Governing_Law": [
        "Patented Medicines (Notice of Compliance) Regulations"
    ],
    "Procedural_Stage": [
        "Application for prohibition order under PM(NOC) Regulations"
    ],
    "Evidence_Assessment": [
        "Weaknesses in affidavits, lack of expert qualification, speculative conclusions, insufficient evidence on physician behavior"
    ],
    "Decision_Outcome": [
        "Application for prohibition order dismissed"
    ],
    "Burden_of_Proof": [
        "Balance of probabilities"
    ],
    "Credibility_Factor": [
        "Lack of proper expert qualification and speculative nature of evidence"
    ],
    "Legal_Rule": [
        "Generic manufacturer can be prohibited from obtaining NOC if patent infringement is established"
    ],
    "Standard_of_Review": [
        "Reasonableness"
    ],
    "Procedural_Issue": [
        "Sufficiency of evidence to justify prohibition"
    ],
    "Grounds_for_Claim": [
        "Alleged infringement of '668 and '762 patents by Apo-Omeprazole tablets"
    ],
    "Outcome_on_Merits": [
        "No sufficient evidence of direct or indirect infringement"
    ],
    "Decision_Maker": [
        "Federal Court"
    ],
    "Judicial_Review_Outcome": [
        "Application dismissed"
    ],
    "Review_Standard": [
        "Balance of probabilities"
    ],
    "Procedural_Fairness_Assessment": [
        "Both parties presented evidence; court evaluated fairness in procedural context"
    ],
    "Key_Evidence_Considered": [
        "Affidavits regarding physician prescribing behavior and patient use"
    ],
    "Legal_Framework": [
        "PM(NOC) Regulations framework for patent disputes in pharmaceutical sector"
    ],
    "Applicant_Challenge": [
        "Seeking to prevent Apotex from obtaining Notice of Compliance"
    ],
    "Court_Result": [
        "Apotex allowed to proceed with obtaining Notice of Compliance"
    ],
    "Legal_Rule_Source": [
        "Patented Medicines (Notice of Compliance) Regulations"
    ],
    "Standard_of_Proof": [
        "Balance of probabilities"
    ],
    "Defendant_Response": [
        "Filed Notice of Allegation asserting non-infringement"
    ],
    "Evidence_Type": [
        "Affidavit evidence, expert opinion (challenged for credibility)"
    ],
    "Remedy_Requested": [
        "Prohibition order to block issuance of Notice of Compliance"
    ],
    "Outcome": [
        "Dismissal of prohibition application"
    ],
    "Decision_Authority": [
        "Federal Court of Canada"
    ],
    "Remedy_Sought": [
        "Interlocutory injunction preventing regulatory approval"
    ],
    "Resolution_Mechanism": [
        "Judicial determination under PM(NOC) proceedings"
    ],
    "Legal_Provision": [
        "Sections of the Patented Medicines (Notice of Compliance) Regulations"
    ],
    "Authority": [
        "Minister of Health (regulatory authority for Notice of Compliance)"
    ],
    "Claimant_Status": [
        "Brand-name pharmaceutical companies (AB Hassle and AstraZeneca Canada Inc.)"
    ],
    "Legal_Provision_Cited": [
        "Patented Medicines (Notice of Compliance) Regulations"
    ],
    "Grounds_for_Inadmissibility_or_Allegation": [
        "Non-infringement of patents due to lack of evidence on use-based infringement"
    ],
    "Applicable_Process": [
        "PM(NOC) proceeding for pre-market patent dispute resolution"
    ],
    "Outcome_of_Review": [
        "No prohibition issued; generic may obtain NOC"
    ],
    "Pending_Relief_or_Application": [
        "Application for prohibition order"
    ],
    "Jurisdiction": [
        "Federal jurisdiction, Canada"
    ],
    "Governing_Rule": [
        "Patented Medicines (Notice of Compliance) Regulations"
    ]
}